Arrowsmith Genetics (AGx) is a preclinical stage precision oncology company exploiting genetics to broaden the therapeutic target repertoire of anti-cancer drugs. Key to the approach is the AGx Mutational Target Mapping (MTM) platform, which optimizes drug targeting strategies, leading to new therapeutic candidates. The company’s platform is fast, suitable for assessing hard-to-target essential and redundant proteins, and finds critical sites that are unique to the targeted protein, thereby minimizing off-target effects. Our current pipeline focuses on converting DNA repair proteins into dominant anti-cancer cytotoxic agents.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 2222 Health Sciences Mall, Amgen/sbme Golden Ticket Incubator,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://twitter.com/ArrowsmithGx
- Keywords
- CereCura Nanotherapeutics.
- HQ
- Vancouver, British Columbia
Arrowsmith Genetics Questions
Arrowsmith Genetics's website is https://twitter.com/ArrowsmithGx
Arrowsmith Genetics's LinkedIn profile is https://ca.linkedin.com/company/arrowsmith-genetics
Arrowsmith Genetics has
3 employees.
View email and phone details for 3
employees at Arrowsmith Genetics.
Arrowsmith Genetics's industry is
Biotechnology Research
Arrowsmith Genetics's top competitors are
Insu Therapeutics,
Smartparent Mobile Health Inc.,
Cerecura Nanotherapeutics,
Amphoraxe Life Sciences Inc.,
Melius Microbiomics,
Arrowsmith Inc.,
Sinedore Medicine 正弦生醫,
Lunar Therapeutics,
Sustainable Bioproduct Innovations,
Sora Fuel.
Arrowsmith Genetics's categories are Biotechnology Research
Arrowsmith Genetics's founding year is 2021
